CNTX - Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
- Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications.
- Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of September of 2021.
- Context Therapeutics debuted last week at a far lower price than originally contemplated, while the sector (XBI) was almost 40% down from its February high.
- In my opinion, this company is undervalued and an opportunity exists to take a position before the larger market realizes the potential within Context's pipeline.
For further details see:
Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential